Hercules Capital, Inc. (HTGC) Hercules Capital, Inc. is a business development company. The firm specializing in providing private equity, venture debt, and growth capital to privately held venture capital-backed companies at all stages of development from mid venture to expansion stage including select publicly listed companies and select special opportunity companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and corporate spin-out financing solutions; company, asset specific, or intellectual property acquisition financing; convertible, subordinated and/or mezzanine loans; domestic and international corporate expansion; vendor financing; revenue acceleration by sales and marketing development, and manufacturing expansion. It provides asset-based financing with a focus on cash flow; accounts receivable facilities; equipment loans or leases; equipment acquisition; facilities build-out and/or expansion; working capital revolving lines of credit; inventory. The firm also provides bridge financing to IPO or mergers and acquisitions or technology acquisition; dividend recapitalizations and other sources of investor liquidity; cash flow financing to protect against share price volatility; competitor acquisition; pre-IPO financing for extra cash on the balance sheet; public company financing to continue asset growth and production capacity; short-term bridge financing; and strategic and intellectual property acquisition financings. It also focuses on customized financing solutions, emerging growth, mid venture, and late venture financing. The firm invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The firm generally seeks to invest in companies that have been operating for at least six to 12 months prior to the date of their investment. It prefers to invest in technology, SaaS Finance, energy technology, sustainable and renewable technology, and life sciences. Within technology the firm focuses on advanced specialty materials and chemicals; communication and networking, consumer and business products; consumer products and services, digital media and consumer internet; electronics and computer hardware; enterprise software and services; gaming; healthcare services; information services; business services; media, content and information; mobile; resource management; security software; semiconductors; semiconductors and hardware; and software sector. Within energy technology, it invests in agriculture; clean technology; energy and renewable technology, fuels, and power technology; geothermal; smart grid and energy efficiency and monitoring technologies; solar; and wind. Within life sciences, the firm invests in biopharmaceuticals; biotechnology tools; diagnostics; drug discovery, drug platform, development, and delivery; medical devices and equipment; surgical devices; therapeutics; pharma services; and specialty pharmaceuticals. Within sustainable and renewables, it invests in Vehicle Technology, Energy Generation and Storage, Ag Technology, Advanced Materials, and Industry 4.0. It also invests in educational services. The firm invests primarily in United States based companies and considers investment in the West Coast, Mid-Atlantic regions, Southeast and Midwest, particularly in the areas of software, biotech, and information services. The firm prefers to invest between $5 million and $500 million in equity per transactions. It invests in debt between $1 million and $40 million in companies focused primarily on business services, communications, electronics, hardware, and healthcare services. The firm invests primarily in private companies but also have investments in public companies. For equity investments, the firm seeks to represent a controlling interest in its portfolio companies which may exceed 25% of the voting securities of such companies. The firm seeks to invest a limited portion of its assets in equipment-based loans to early-stage prospective portfolio companies. These loans are generally for amounts up to $3 million but may be up to $15 million for certain energy technology venture investments. The firm allows certain debt investments have the right to convert a portion of the debt investment into equity. It also co-invests with other private equity firms. The firm seeks to exit its investments through initial public offering, a private sale of equity interest to a third party, a merger or an acquisition of the company or a purchase of the equity position by the company or one of its stockholders. The firm has structured debt with warrants which typically have maturities of between two and seven years with an average of three years; senior debt with an investment horizon of less than three years; equipment loans with an investment horizon ranging from three to four years; and equity related securities with an investment horizon ranging from three to seven years. The firm prefers to invest through its balance sheet capital. The firm formerly known as Hercules Technology Growth Capital, Inc. Hercules Capital, Inc. was founded in December 2003 and is based in San Mateo, California with additional offices in North America and Europe.
Industry: Asset Management
Hercules Capital, Inc. NYSE:HTGC Financial Services · Asset Management
Mkt Cap $3.07B
Div Yield 11.88%
AH Close $16.41 +0.00% vs close
AH Close $16.41 +0.00% vs close
Mkt Cap $3.07B
Div Yield 11.88%
All Press Release SEC Filings News
Press Release
Hercules Capital Receives Affirmed BBB- Investment Grade Corporate and Unsecured Credit Rating from Fitch Ratings, Inc.
Fitch affirmed Hercules Capital's BBB- investment grade corporate and unsecured credit rating and BBB secured debt rating with a stable outlook.
The affirmation cites Hercules' first-lien portfolio focus, credit track record, funding flexibility, and above-average asset coverage cushion.
No new rating action or financing was announced; this is a routine credit confirmation relevant to holders of the 6.25% Notes due 2033 (HCXY).
• 9d ago AI analysis › News
Hercules Capital (HTGC) Exceeds Market Returns: Some Facts to Consider
zacks.com • 10d ago Press Release
Hercules Capital Announces Date for Release of Third Quarter 2026 Financial Results and Conference Call
Hercules Capital scheduled its third quarter 2026 financial results release and conference call for Thursday, October 29, 2026, with results to be issued after market close that day.
The call will be held at 2:00 p.m. PT (5:00 p.m. ET), with a live webcast available on the company's investor relations site and a dial-in conference ID of HTGCQ326.
Hercules' retail bond (NYSE: HCXY) trades alongside the common stock (NYSE: HTGC); this notice is administrative and contains no results.
• 10d ago AI analysis › News
Hercules Capital (HTGC) Advances While Market Declines: Some Information for Investors
zacks.com • 17d ago Press Release ⚠ 2
Hercules Capital Closes Institutional Notes Offering of $400.0 Million 6.700% Notes due 2029
Hercules Capital closed an upsized $400.0 million public offering of 6.700% unsecured notes due October 8, 2029.
The notes received initial ratings of Baa2 from Moody's and BBB- from Fitch, and proceeds will repay existing debt, fund investments, and support general corporate purposes.
Goldman Sachs, SMBC Nikko and MUFG acted as joint book-runners. Note the primary ticker here is HCXY, Hercules' listed 6.25% retail notes due 2033, while the operating company trades as HTGC.
• 17d ago AI analysis › Press Release ⚠ 2
Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital
Hercules Capital (HTGC) has agreed to provide Rocket Pharmaceuticals a credit facility of up to $150 million, with $35 million funded at closing.
The deal is staged: a $35M optional draw, a $30M tranche tied to a Danon disease clinical milestone, and a $50M tranche pending Hercules' investment committee approval, with a 30-month interest-only period and 48-month maturity plus warrants.
For HTGC, this is a routine life-sciences venture-debt origination that deploys capital into a commercial-stage biotech borrower; Rocket's cash runway extends into Q3 2028, potentially 2029 with additional draws.
• 19d ago AI analysis › Press Release ⚠ 2
Hercules Capital Prices Upsized Institutional Notes Offering of $400.0 Million 6.70% Notes due 2029
Hercules Capital priced an upsized $400.0 million public offering of 6.70% unsecured notes due October 8, 2029, with settlement expected October 8, 2026.
Proceeds are earmarked to repay outstanding secured and unsecured indebtedness, fund new investments consistent with its venture-lending objectives, and for general corporate purposes.
Goldman Sachs, SMBC Nikko and MUFG Securities are joint book-runners; the new notes are redeemable at par plus any make-whole premium.
• 20d ago AI analysis › News
Comparing LPL Financial (NASDAQ:LPLA) and Hercules Capital (NYSE:HTGC)
defenseworld.net • 21d ago News
West Virginia American Water Announces $166,000 Infrastructure Project in Fayetteville
gurufocus.com • 23d ago Press Release
NorthStar Secures Up to $185 Million Growth Financing Led by Hercules Capital to Scale Actinium-225 Production and Radiopharmaceutical Manufacturing for Next-Generation Precision Cancer Therapies
Hercules Capital (NYSE: HTGC) is leading an up-to-$185 million multi-year growth capital facility for NorthStar Medical Technologies, with $100 million upfront.
NorthStar will use the capital to scale commercial production of no-carrier-added Actinium-225 and expand its vertically integrated radiopharmaceutical campus and CDMO in Beloit, Wisconsin.
For HTGC, this is a new venture-debt origination adding a commercial-stage radiopharmaceutical borrower with more than 30 pharma and biotech customers to the portfolio.
• 26d ago AI analysis › News
Is It Worth Investing in Hercules Capital (HTGC) Based on Wall Street's Bullish Views?
zacks.com • 0mo ago News
Hercules Capital (HTGC) Dips More Than Broader Market: What You Should Know
zacks.com • 1mo ago News
Here's Why Hercules Capital (HTGC) Fell More Than Broader Market
zacks.com • 1mo ago News
Hercules Capital (HTGC) Advances But Underperforms Market: Key Facts
zacks.com • 1mo ago Press Release
Hercules Capital Announces the Appointment of Alfred B. Fichera to Its Board of Directors
Hercules Capital appointed Alfred B. Fichera as an independent member of its board of directors, effective September 17, 2026, and he will serve on the Audit Committee.
Fichera brings more than 40 years in financial services and asset management, including a 1982-2019 career at KPMG LLP as Global Head of Alternative Investments, and has chaired the audit committee of Warburg Pincus Access Fund since September 2025.
This is a routine governance addition with no disclosed financial or strategic impact for the specialty finance BDC, whose common stock trades as HTGC and whose 6.25% Notes due 2033 trade as HCXY.
• 1mo ago AI analysis › News
Hercules Capital (HTGC) Suffers a Larger Drop Than the General Market: Key Insights
zacks.com • 1mo ago News
Is Hercules Capital (HTGC) a Buy as Wall Street Analysts Look Optimistic?
zacks.com • 1mo ago Press Release ⚠ 1
Hercules Capital’s Investment Adviser Surpasses $2.3 Billion in Investable Capital
Hercules Adviser LLC, the wholly-owned registered investment adviser of Hercules Capital (NYSE: HTGC), has surpassed $2.3 billion in investable capital following closings across the new Hercules Evergreen Fund, Hercules Growth Lending IV, and a rated securitization.
The Evergreen Fund is the adviser's inaugural perpetual, open-end vehicle and its fifth institutional private credit vehicle since the platform was created in 2021; together with Hercules Capital, the firm now manages approximately $6.1 billion of assets.
The milestone broadens the fee-bearing capital base around HTGC's growth-lending platform, which has committed over $28.0 billion to more than 700 portfolio companies as of June 30, 2026, though the release does not quantify fee economics or direct earnings impact for the BDC.
• 1mo ago AI analysis › News
Hercules Capital: Why It Deserves A Premium To NAV Valuation
seekingalpha.com • 1mo ago News
Hercules Capital Outperformed My Expectations But I'm Not Buying
seekingalpha.com • 1mo ago News
Hercules Capital: 11% Yield Backed By Record Performance
seekingalpha.com • 1mo ago News
Hercules Capital, Inc. (NYSE:HTGC) Given Consensus Recommendation of “Moderate Buy” by Brokerages
defenseworld.net • 1mo ago Press Release
Hercules Capital Receives a BBB+ Affirmed Investment Grade Corporate and Credit Rating from Kroll Bond Rating Agency, Inc.
Kroll Bond Rating Agency affirmed Hercules Capital's investment-grade corporate and credit rating at BBB+ with a stable outlook.
The rating reflects the company's diversified portfolio of senior secured venture debt, its 23+ year operating history, and appropriate leverage metrics.
Management highlighted that the rating is supported by robust risk management, access to capital markets, and a high proportion of senior unsecured debt.
• 2mo ago AI analysis › News
Hercules Capital: Portfolio Metrics Warrant An Upgrade To Buy
seekingalpha.com • 2mo ago News
Hercules Capital: 0.1% Non-Accruals, 125% Coverage, Top BDC Value
seekingalpha.com • 2mo ago News
Hercules Capital: Net Asset Value And Dividend Coverage Expands
seekingalpha.com • 2mo ago News
Hercules Capital: The Software Panic Was Overblown
seekingalpha.com • 2mo ago News
Hercules Capital: Strong Growth But Valuation Leaves Little Room For Error
seekingalpha.com • 2mo ago News
BDC Weekly Review: Hercules Capital Posts Strong Q2 Results
seekingalpha.com • 2mo ago News
HTGC Q2 Earnings Meet Estimates, Stock Up on Record Investment Income
zacks.com • 2mo ago News
Hercules Capital Q2 Earnings Call Highlights
marketbeat.com • 2mo ago News
Hercules Capital, Inc. (HTGC) Q2 2026 Earnings Call Transcript
seekingalpha.com • 2mo ago News
Hercules Capital (HTGC) Q2 Earnings Meet Estimates
zacks.com • 2mo ago SEC Filing
HTGC: 10-Q · periodic report
Hercules Capital reported solid financial results for the six months ended June 30, 2026, with total investment income increasing 13% to $290.7 million compared to the prior year period. Net investment income rose to $181.0 million, or $0.97 per basic share, driven by higher interest income across the debt investment portfolio. Net asset value per share grew slightly to $12.15 from $12.13 at year-end 2025, reflecting accrued income and new capital raises.
The company's investment portfolio remained robust at approximately $4.58 billion in fair value, with significant concentrations in Drug Discovery & Development and Healthcare Services. Total assets reached $4.69 billion, supported by $2.34 billion in total debt and $48.2 million in cash and cash equivalents. The company maintained its dividend policy, distributing $174.7 million, or $0.94 per share, to shareholders during the period.
Operational cash flow remained positive, and the company continued to actively manage its portfolio through new originations and repayments. The balance sheet reflects a typical business development company structure with leverage ratios within regulatory targets, positioning Hercules to capitalize on new investment opportunities in the specialty finance market.
SEC 10-Q • 2mo ago AI analysis › Press Release ● Major
Hercules Capital Reports Second Quarter 2026 Financial Results
Hercules Capital reported record Q2 2026 financial results with total investment income of $149.1 million and net investment income of $92.9 million, up 8.5% and 4.7% year-over-year respectively.
The company achieved record first-half new debt and equity commitments of $2.74 billion, driving total fundings of $1.35 billion, while assets under management grew 14.4% to approximately $6.1 billion.
Q2 NII of $0.50 per share provided 125% coverage of the base cash distribution, supported by conservative balance sheet management with net GAAP leverage at 101.8%.
• 2mo ago AI analysis › Press Release
Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the Second Quarter 2026
Hercules Capital declared a second quarter 2026 total cash distribution of $0.47 per share, comprised of $0.40 base and $0.07 supplemental distributions.
The record date is set for August 11, 2026, with payments scheduled for August 18, 2026, adhering to the company's variable distribution policy aimed at distributing 90% to 100% of taxable income.
Management noted that 78.65% of year-to-date distributions are Qualified Interest Income, exempt from U.S. withholding tax for documented non-U.S. shareholders.
• 2mo ago AI analysis › News
Blue-Chip 12% Yields: Why I Give Hercules Capital The Edge Over Trinity Capital
seekingalpha.com • 3mo ago Press Release
Hercules Capital Closes Institutional Notes Offering of $325.0 Million 6.300% Unsecured Notes due 2031
Hercules Capital closed a $325 million public offering of 6.300% unsecured notes due July 2031.
The Notes received initial investment-grade ratings of Baa2 from Moody’s and BBB- from Fitch.
Proceeds from the offering will be used to repay outstanding indebtedness, fund new investments, and for general corporate purposes.
• 3mo ago AI analysis › News
Hercules Capital (HTGC) Falls More Steeply Than Broader Market: What Investors Need to Know
zacks.com • 3mo ago Press Release
Hercules Capital Prices Institutional Notes Offering of $325.0 Million 6.300% Notes due 2031
Hercules Capital priced a $325 million offering of 6.300% unsecured notes due July 2031.
The notes bear interest at a rate of 6.300% per year, payable semiannually, and are callable at the company's option at par plus a make-whole premium.
Net proceeds from the offering are expected to be used to repay outstanding indebtedness, fund investments, and for general corporate purposes.
• 3mo ago AI analysis › SEC Filing ⚠ 1
HTGC: 8-K · earnings release
Hercules Capital released preliminary financial results for the second quarter of 2026, reporting an estimated increase in net asset value per share to between $12.10 and $12.20. This represents an increase of $0.20 to $0.30 per share, or 1.7% to 2.5%, from the $11.90 NAV per share reported as of March 31, 2026.
The company estimates second quarter net investment income of $0.49 to $0.51 per share and net realized gains of approximately $7.7 million. Investment activity remained strong with gross new investment commitments and fundings of approximately $0.9 billion and $0.6 billion, respectively.
Credit quality metrics showed a slight deterioration, with investments on non-accrual status rising to less than 0.5% of the total portfolio at cost, up from 0.2% in the prior quarter. Total investments at fair value were preliminarily estimated at $4.5 billion to $4.6 billion as of June 30, 2026.
SEC 8-K • 3mo ago AI analysis › News
Hercules Capital (HTGC) Advances While Market Declines: Some Information for Investors
zacks.com • 3mo ago Press Release
Hercules Capital Announces Date for Release of Second Quarter 2026 Financial Results and Conference Call
Hercules Capital announced it will release its second quarter 2026 financial results after the market closes on July 30, 2026.
The company will host a conference call to discuss the results at 5:00 p.m. ET on the same day.
Investors can access the live webcast via the company's website or participate by phone using conference ID HTGCQ226.
• 3mo ago AI analysis › News
Hercules Capital (HTGC) Stock Dips While Market Gains: Key Facts
zacks.com • 3mo ago Press Release ● Major
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
4D Molecular Therapeutics entered into a strategic credit facility with Hercules Capital for up to $200 million, featuring an initial $20 million draw and additional tranches available through mid-2027 and upon milestone achievements.
The company's current cash position of $458 million, combined with this non-dilutive capital, is expected to fund operations into the second half of 2028, providing flexibility for Phase 3 development.
Proceeds will support the advancement of lead product candidate 4D-150 for wet age-related macular degeneration and diabetic macular edema.
• 3mo ago AI analysis › News
Hercules Capital (HTGC) Advances While Market Declines: Some Information for Investors
zacks.com • 3mo ago News
Brokers Suggest Investing in Hercules Capital (HTGC): Read This Before Placing a Bet
zacks.com • 4mo ago News
Hercules Capital: This 12% Yield Is My Top Pick For The Back Half
seekingalpha.com • 4mo ago News
Hercules Capital Faces Its Own 12 Labors
seekingalpha.com • 4mo ago SEC Filing
HTGC: 8-K · proxy statement
Hercules Capital held its 2026 Annual Meeting of Stockholders on June 18, 2026, with 187,133,158 shares outstanding and entitled to vote as of the record date.
Stockholders elected Robert P. Badavas to serve as a Class I independent director until 2029 and approved the company's executive compensation on an advisory basis.
The meeting also approved amendments to the 2018 Equity Incentive Plan and the 2018 Non-Employee Director Plan, and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2026.
SEC 8-K • 4mo ago Press Release
Behavox Raises $175 Million from HPS Investment Partners, Part of BlackRock, to Accelerate Global Growth
Behavox fully repaid and retired its $70 million venture-debt facility with Hercules Capital, following a $175 million preferred equity investment from HPS Investment Partners.
The repayment comes after a year of strong commercial momentum for Behavox, which grew its customer base 86% to over 100 major financial institutions and has been profitable since 2023.
Hercules Capital Managing Director Ruslan Sergeyev called the partnership highly successful and expressed interest in future collaborations with Behavox.
• 4mo ago AI analysis › Press Release
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
Dyne Therapeutics amended its senior secured term loan facility with Hercules Capital to increase total capacity to $400 million, immediately funding $50 million in non-dilutive capital.
The expansion adds $125 million in new borrowing capacity, split between a milestone-based tranche and a discretionary tranche, while keeping total current borrowings at $200 million.
This financial flexibility is intended to support the advancement of DYNE-251 for Duchenne muscular dystrophy and DYNE-101 for myotonic dystrophy type 1 through upcoming clinical milestones and potential U.S. launches.
• 4mo ago AI analysis › Press Release ● Major
Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C
Hercules Capital (HTGC) entered into a $165 million financing agreement with Beren Therapeutics to support the potential commercial launch of adrabetadex.
The facility consists of a $110 million senior-secured debt term loan and a $55 million royalty financing, providing Beren with non-dilutive capital ahead of its November 2026 FDA decision.
This transaction adds a significant, high-quality life sciences asset to HTGC’s portfolio, with returns tied to regulatory milestones and future sales royalties.
• 4mo ago AI analysis › Press Release
Perk Secures $300 Million Credit Facility to Accelerate Global Growth of Its AI-Native Platform
Perk, a private AI-native travel and spend management platform, closed a $300 million private credit facility.
Hercules Capital (HTGC) is listed as one of the co-lenders alongside Neuberger Speciality Finance, Blue Owl Capital, and Liquidity.
The facility replaces Perk’s prior credit facility on improved terms and will fund global growth and AI product investment. This is a standard portfolio deployment for HTGC and carries no direct material impact on the filer’s financials.
• 4mo ago AI analysis › 44 law-firm class-action alerts 2 fund position changes (13F filings)Recent SEC filings with analysis